BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 19, 2026
Breaking News: Bundibugyo is harsh reminder of need for broad vaccine strategiesBreaking News: Bundibugyo is harsh reminder of need for broad vaccine strategiesBreaking News: Bundibugyo is harsh reminder of need for broad vaccine strategies
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Neurology/Psychiatric

Onsero Therapeutics divulges new 5-HT2A receptor agonists

Aug. 18, 2023
Onsero Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, anxiety, substance abuse and dependence, and headache.
Read More
Cancer

Ionova scientists patent new RAS modulators for cancer

Aug. 18, 2023
Researchers at Foshan Ionova Biotherapeutics Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have disclosed fused heterocyclic compounds acting as RAS modulators reported to be useful for the treatment of cancer.
Read More
Cancer cells under magnifying glass
Cancer

Novel potent dual antagonist of the A2A and A2B receptors presented at ACS

Aug. 18, 2023
Targeting the adenosine A2A receptor, a critical mediator of immunosuppression on the tumor microenvironment, has emerged as a strategy to improve cancer immunotherapy, and several A2A receptor antagonists are under clinical evaluation both as monotherapy and in combination with checkpoint inhibitors.
Read More
Liver anatomy illustration
Cancer

Nuvectis Pharma's NXP-800 granted orphan drug designation for cholangiocarcinoma

Aug. 18, 2023
The FDA has granted orphan drug designation to Nuvectis Pharma Inc.'s NXP-800 for the treatment of cholangiocarcinoma.
Read More
Art concept for inflamed human tissue
Inflammatory

Anti-TNF-α macrocyclic peptide with novel binding mode presented

Aug. 18, 2023
Tumor necrosis factor-α (TNF-α) is a cytokine involved in the regulation of inflammation in several autoimmune and inflammatory disorders such as rheumatoid arthritis, ulcerative colitis, or psoriasis. Anti-TNF biological treatments in place are effective but there is a need for alternatives with novel pharmacological profiles to overcome their limitations.
Read More
3D rendering showing osteoporosis in the femur
Musculoskeletal

Osteoporosis target gene CD109 identified by convergent analyses

Aug. 18, 2023
Researchers working at the Lady Davis Institute, Jewish General Hospital, McGill University, have combined whole-exome sequencing (WES) from nearly 300,000 samples from the multiancestry UK Biobank, with ultrasound-derived heel estimated bone mineral density (eBMD) and genome-wide association (GWAS) data to identify potential future therapeutic targets for patients with osteoporosis.
Read More
Antibodies attacking cancer cell
Immuno-oncology

Novarock's bispecific antibody NBL-028 cleared to enter clinic for CLDN6-expressing tumors

Aug. 18, 2023
Novarock Biotherapeutics Ltd., a subsidiary of CSPC Pharmaceutical Group Ltd., has received FDA approval of its IND application for NBL-028, a CLDN6-CD137 bispecific antibody.
Read More
Neurology/Psychiatric

Gene therapy shows early promise for treating severe alcohol addiction

Aug. 18, 2023
By Helen Albert
Research in rhesus monkeys has shown a gene therapy that enhanced activity in dopamine producing neurons in the brain was effective at stopping excessive alcohol consumption in previously addicted animals.
Read More
AI-generated art of brain connections
Neurology/Psychiatric

Brain maps uncover individual differences in psychiatric disorders

Aug. 18, 2023
By Mar de Miguel
The study of six types of mental illnesses in a thousand brain regions has demonstrated the differences between individuals within each disorder. Using magnetic resonance images (MRI), scientists from Monash University in Australia analyzed the brain changes and built individual maps for each psychiatric disorder. Their results revealed differences between people with the same diagnosis, which could help refine assessments.
Read More

Other news to note for Aug. 18, 2023

Aug. 18, 2023
Additional early-stage research and drug discovery news in brief, from: Excision Biotherapeutics.
Read More
Previous 1 2 … 990 991 992 993 994 995 996 997 998 … 18071 18072 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 18, 2026.
  • DNA and genome editing illustration

    ASGCT 2026: Directed evolution in gene therapy

    BioWorld
    Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • Doctor with brain illustration, businessman with dollar sign illustration

    Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal

    BioWorld
    Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
  • Illustration of tau accumulating in a neuron cell.

    Biogen AD drug shows tau, cognition benefit, despite trial miss

    BioWorld
    Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing